Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial. (Q42877987)

From Wikidata

Jump to navigation Jump to search

scientific article published on 21 September 2010

Language	Label	Description	Also known as
English	Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial.	scientific article published on 21 September 2010

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20864406%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20864406%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

phase III clinical trial

0 references

multicenter clinical trial

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20864406%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20864406%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20864406%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

1

object named as

Axel Le Cesne

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20864406%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Isabelle Ray-Coquard

2

object named as

Isabelle Ray-Coquard

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20864406%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Florence Duffaud

7

object named as

Florence Duffaud

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20864406%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

François Bertucci

6

object named as

François Bertucci

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20864406%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Christine Chevreau

8

object named as

Christine Chevreau

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20864406%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Didier Cupissol

9

object named as

Didier Cupissol

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20864406%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Jean-François Emile

12

object named as

Jean-François Emile

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20864406%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

French Sarcoma Group

16

object named as

French Sarcoma Group

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20864406%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

4

object named as

Antoine Adenis

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20864406%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

14

object named as

David Pérol

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20864406%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

13

object named as

Sylvie Chabaud

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20864406%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

author name string

Binh Nguyen Bui

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20864406%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Maria Rios

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20864406%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

publication date

21 September 2010

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20864406%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Lancet Oncology Commission

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20864406%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20864406%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20864406%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

942-949

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20864406%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970222-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970222-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Diagnosis of gastrointestinal stromal tumors: A consensus approach

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970222-9

7 January 2021

based on heuristic

inferred from DOI database lookup

PDGFRA activating mutations in gastrointestinal stromal tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970222-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970222-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970222-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970222-9

7 January 2021

based on heuristic

inferred from DOI database lookup

KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970222-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970222-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970222-9

7 January 2021

based on heuristic

inferred from DOI database lookup

KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970222-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970222-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970222-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970222-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970222-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970222-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970222-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970222-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Gastrointestinal stromal tumors treated with imatinib: monitoring response with contrast-enhanced sonography

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970222-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Metastatic renal cell carcinoma treated with sunitinib: early evaluation of treatment response using dynamic contrast-enhanced ultrasonography

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970222-9

7 January 2021

based on heuristic

inferred from DOI database lookup

The development of imatinib as a therapeutic agent for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970222-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970222-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970222-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970222-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Deletions affecting codons 557-558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Research (GEIS).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970222-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2810%2970222-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42877987&oldid=1835244028"